Judge Grants Hearing for Opposition to DEA Proposal to Criminalize 5 More Psychedelics
Biotech companies and researchers opposed to five more tryptamines becoming schedule 1 controlled substances will present their case this spring.
Biotech companies and researchers opposed to five more tryptamines becoming schedule 1 controlled substances will present their case this spring.
“These fungi pose less potential safety risks to consumers,” says Psilocybin Advisory Board mycologist Jessie Uehling.
The Psychedelic CEO Round Table | feat. MindMed, Cybin, Field Trip and the Psychedelic Investor
Join the Psychedelic Investor and the CEOs of MindMed (Rob Barrow) and Cybin (Doug Drysdale), and the Executive Chairman of Field Trip (Ronan Levy) as they discuss the future of psychedelic medicines.
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
If you are interested in investing in psychedelic stocks, then this is the even for you. Full of knowledge and unique information, this CEO discussion is a must.
Learn about the companies behind MindMed’s stock (Nasdaq: MNMD, NEO: MMED), Cybin’s stock (NYSE: CYBN, NEO: CYBN) and Field Trip Health’s stock (Nasdaq: FTRP, TSX: FTRP).
Presented by PsychedelicSpotlight.com, this conversation is as great a starting place as any to learn about psychedelic stocks
#Psychedelics #MindMed #Investing
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.